Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 9/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722782 | 0.82 | IRAK4 (0.35) | FFAR1DGAT1AAK1ALPLIRAK4 | |
| SCHEMBL2068803 | 0.80 | APP (0.39) | FFAR1DGAT1AAK1ALPLIRAK4 | |
| SCHEMBL720459 | 0.79 | PDGFRB (0.37) | FFAR1DGAT1ALPLIRAK4LPL | |
| SCHEMBL1960853 | 0.75 | CCR1 (0.39) | — | |
| SCHEMBL12537323 | 0.74 | PDGFRB (0.39) | FFAR1DGAT1ALPLIRAK4LPL | |
| SCHEMBL30179105 | 0.74 | PDGFRB (0.41) | FFAR1DGAT1ALPLIRAK4LPL | |
| SCHEMBL4831595 | 0.74 | ALPL (0.38) | FFAR1DGAT1ALPLIRAK4LPL | |
| SCHEMBL1665957 | 0.74 | FGFR1 (0.35) | IRAK4 | |
| SCHEMBL15328787 | 0.73 | PDGFRB (0.36) | FFAR1DGAT1IRAK4LPLLIPG | |
| SCHEMBL25316539 | 0.73 | DGAT1 (0.32) | FFAR1DGAT1AAK1ALPLIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257545-B1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | SLC6A3, MAOB, TPH2 | FFAR1 3197/4885DGAT1 3226/4885AAK1 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.